Volume 15.48 | Dec 8

Immunotherapy Achieves Breakthrough Result in Patients with Hodgkin Lymphoma
A therapy that liberates the immune system to attack cancer cells drove Hodgkin lymphoma into complete or partial remission in fully 87 percent of patients with resistant forms of the disease who participated in an early-phase clinical trial. The results provide some of the most dramatic evidence to date of the potential of therapies that increase the ability of the immune system to kill cancer cells. [Press release from Dana-Farber Cancer Institute discussing online prepublication in the New England Journal of Medicine] Press Release|Video|Abstract

Benefits Persist in T Cell Therapy for Children with Relapsed Leukemia
An innovative cell therapy against a highly aggressive form of acute lymphoblastic leukemia continues to show highly promising results in children treated in a pilot study. Ninety-two percent of the 39 children receiving bioengineered T cells had no evidence of cancer at one month after treatment, with this complete response persisting in some cases for more than two years. [Press release from EurekAlert discussing research presented at the annual meeting of the American Society of Hematology (ASH), San Francisco] Press Release